India investing $1.3B to cut dependence on Chinese APIs by Eric Palmer Monday, March 23, 2020 With the COVID-19 outbreak having put pressure on prices and supplies, India is now doing something to wean itself away from Chinese APIs.
India export, Roche's Actemra, Takeda and more—FiercePharmaAsia by Angus Liu Friday, March 6, 2020 India curbs export of 26 active ingredients and drugs. China uses Roche's Actemra against COVID-19. Takeda nets $940 million through asset sales.
India's restrictions on API exports only temporary: report by Eric Palmer Thursday, March 5, 2020 India’s curb on the export of 26 APIs in the face of the COVID-19 should utbreak has reverberated through the drug manufacturing industry.
Coronavirus spurs India to restrict exports of 2 dozen drugs by Eric Palmer Tuesday, March 3, 2020 India has come up with a surprise in the face of the coronavirus outbreak by curbing the export of 26 APIs and their formulations.
FDA reports first drug shortage tied to COVID-19 by Eric Palmer Friday, February 28, 2020 The world’s reliance on cheap Chinese ingredients has materialized in the U.S., as the FDA reports the first shortage of a drug due to the COVID-19.
Sandoz pledges 'stable' pricing amid COVID-19 outbreak by Eric Sagonowsky Thursday, February 27, 2020 To help allay supply chain concerns from the novel coronavirus, Sandoz pledged "stable" pricing on certain generics and antibiotics.
FDA anticipates disruptions, shortages as China outbreak builds by Eric Palmer Monday, February 17, 2020 The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.
Concern for drug shortages grows as COVID-19 outbreak drags on by Eric Palmer Friday, February 14, 2020 While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.
Don't expect Natpara supply in the U.S. for another year: Takeda by Angus Liu Tuesday, February 4, 2020 Recent discussions with the FDA suggest a delay resuming Natpara supply in the U.S. beyond March 2021, Takeda's CFO said.
Virus-stricken China's key to pharma's supply. Should we worry? by Angus Liu Monday, February 3, 2020 As the new coronavirus spreads in China, the world's major makers of drug ingredients, pharmas, are monitoring their supplies.
